ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Tetrazine Functionalized Graphene Enables Capture of Ultra-Low Concentrations of Biomacromolecules.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Monolayer graphene has great potential for a range of technological and biomedical applications. To achieve this potential, however, selective functionalization of the surface using mild chemical methods that yield spatially and chemically well-defined functional groups is needed. Here, we describe a method to densely and uniformly modify the surface of graphene using a diazonium salt containing a tetrazine moiety, a functional group amenable to bioorthogonal chemistry. The resulting functionalized graphene efficiently undergoes inverse electron demand Diels-Alder reactions with trans-cyclooctene (TCO) coupled compounds, including a small organic molecule and an anti-GFP nanobody. The nanobody decorated graphene readily captures EGFP tagged apoferritin (EGFP apo-Ftn) and by following the binding by total internal fluorescence microscopy, we demonstrate that the functionalized graphene can robustly capture EGFP apo-Ftn molecules at a concentration of 2 pm.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.